RecruitingNCT00131014

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies

Sponsor

Dana-Farber Cancer Institute

Enrollment

1,500 participants

Start Date

Aug 9, 2004

Study Type

OBSERVATIONAL

Conditions

Lymphoproliferative Disorders Non-Hodgkin's Lymphoma Hodgkin's Disease Leukemia, Lymphocytic, Chronic

Summary

The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is establishing a tissue and blood bank from families with multiple cases of lymphoma (a blood cancer) to identify genetic factors that may increase the risk of these cancers. **You may be eligible if...** - You are over 18 years of age - You have been diagnosed with non-Hodgkin's lymphoma, Hodgkin's disease, or chronic lymphocytic leukemia (CLL), AND have a first-degree relative (parent, sibling, or child) with a similar blood cancer - You are a family member (affected or unaffected with lymphoma) willing to participate - Deceased family members may be included using medical records or archived tissue (with next-of-kin consent) **You may NOT be eligible if...** - You do not have a family history of lymphoma Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT00131014

Related Trials

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

NCT040029471 location

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

NCT025799672 locations

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

NCT039227242 locations

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

NCT018904861 location

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

NCT0307569638 locations